InvestorsHub Logo
Followers 136
Posts 14063
Boards Moderated 0
Alias Born 09/14/2011

Re: None

Thursday, 09/12/2019 9:57:11 AM

Thursday, September 12, 2019 9:57:11 AM

Post# of 2791
$NBIO a biopharmaceutical company focusing on the development of monoclonal antibodies for the treatment of various types of cancers, announces an agreement with TRITON FUNDS LP. TRITON FUNDS LP will invest $1 million to support the commencement of Phase I human clinical studies on Nascent’s primary asset, Pritumumab.

New Board for anyone to Post responsible plays

http://investorshub.advfn.com/boards/board.aspx?board_id=22648

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBIO News